Patent settlements accelerate the entry of generics and biosimilars, saving the health care system $422.9 billion and ...

Denosumab biosimilars Wyost and Jubbonti launch in the US, enhancing access to affordable treatments for osteoporosis and ...

New research confirms denosumab biosimilar SB16 matches Prolia in efficacy, offering a cost-effective treatment option for ...

Biosimilar associations advocate for lower development costs and streamlined regulations to enhance patient access to ...

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

Starjemza gains FDA approval as the eighth ustekinumab biosimilar, enhancing treatment options for rheumatic and ...

FDA approvals for new biosimilars like Starjemza and Hadlima enhance treatment options, addressing urgent needs for ...

Number 5: Cimerli offers a promising biosimilar treatment for age-related macular degeneration, enhancing vision preservation ...

Holz, MD, discussed the rationale and safety surrounding the automatic substitution of biosimilars at the pharmacy level, as well as common misconceptions about these medications.